Broadcom (BRCM) was upgraded at Drexel Hamilton to buy from hold. Twelve-month price target is $45. Shedding the cellular baseband business highlights the growth potential in high-speed data, Drexel Hamilton said.

Coach (COH) was downgraded at Sterne Agee to neutral. Twelve-month price target is $41. Sales visibility remains low and a potential turnaround lies too far out, Sterne Agee said.

ITT(ITT) - Get Report was upgraded to buy at TheStreet Ratings.

GNC(GNC) - Get Report was initiated with a buy rating at Bank of America/Merrill Lynch. Consistent growth and long-term drivers in the hardlines retail sector create an opportunity to accelerate comp sales and expand the multiple, Bank of America/Merrill Lynch said. Twelve-month price target is $50.

Monster Beverage(MNST) - Get Report was initiated with an outperform rating at Credit Suisse. Twelve-month price target is $82. Company can deliver industry-leading top- and bottom-line growth, Credit Suisse said.

[Read: Ciena Continues to Feel Pressure From Weak Carrier Spending]

WATCH: More market update videos on TheStreet TV | More videos from Ruben Ramirez

Newell Rubbermaid(NWL) - Get Report was upgraded at Morgan Stanley to overweight from equal-weight. Twelve-month price target is $34. Expect organic sales and earnings growth to rebound in the coming quarters, Morgan Stanley said.

SciQuest (SQI) was downgraded to hold at TheStreet Ratings.

Tibco (TIBX) was downgraded at MIzuho to neutral. Twelve-month price target is $18. Company faces execution challenges, Mizuho said.

Tibco was downgraded at Stifel Nicolaus to hold from buy. Company is seeing lower Spotfire demand, Stifel Nicolaus said.

[Read: European Stocks Fall on Growth Slowdown]

Tibco was downgraded at JMP Securities to market perform from outperform. Company is losing market share and investments have not paid off, JMP Securities said.

Under Armour(UA) - Get Report was upgraded at Jefferies to buy from hold. Driven by LT revenue growth potential, Jefferies said. Twelve-month price target is $65.

Vitamin Shoppe(VSI) - Get Report was upgraded at Bank of America/Merrill Lynch to neutral from underperform. Twelve-month price target is $47. Worst of the comp and margin pressure appears to be behind the company, BofA/Merrill said.

Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.

Follow TheStreet on Twitter and become a fan on Facebook.

>>Read More: Boring Market? Careful What You Wish For

>>Read More: Why Apple Continuity Among Its Top-Tier Products Is Great for Investors

This article was written by a staff member of TheStreet.